Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the FDA revisits its decision to remove it.

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of ...

周四，Leerink Partners维持了对制药巨头礼来（NYSE:LLY）的"跑赢大市"评级和990.00美元的目标价。该公司的立场是基于英国最近的动向，英国计划评估礼来的药物tirzepatide对肥胖症造成的经济压力的影响。

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

Leerink Partners维持礼来(NYSE: LLY)股票"跑赢大市"评级，目标价保持在$990.00不变。该公司在预期礼来第三季度业绩时调整了其财务模型。

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...